Does Dr. MICHAEL ALDRIDGE have financial conflicts of interest?

Dr. MICHAEL ALDRIDGE (M.D.) has received a total of $615 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $615 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MICHAEL ALDRIDGE?

According to CMS Open Payments data, Dr. MICHAEL ALDRIDGE received funding from ASTRAZENECA PHARMACEUTICALS ($172), NOVARTIS PHARMACEUTICALS CORPORATION ($164), and BOSTON SCIENTIFIC CORPORATION ($58).

Does Dr. MICHAEL ALDRIDGE receive research grants or speaking fees?

Dr. MICHAEL ALDRIDGE has received $615 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MICHAEL ALDRIDGE

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Cardiovascular Disease

Practice Location: SANTA BARBARA, CA 93105

NPI Number: 1033427067

LIFETIME INDUSTRY VALUE

$615

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ALDRIDGE is a verified Internal Medicine, Cardiovascular Disease practitioner based in SANTA BARBARA, CA.

Between 2021 and 2024, Dr. ALDRIDGE had an overall industry promotional and research financial footprint of $615 as recorded in the federal CMS Open Payments database.

$615 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ALDRIDGE's primary funding source is ASTRAZENECA PHARMACEUTICALS, which accounts for $172 (representing 27.9% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ASTRAZENECA PHARMACEUTICALS

Rank 1

$172

27.9%

NOVARTIS PHARMACEUTICALS CORPORATION

Rank 2

$164

26.7%

BOSTON SCIENTIFIC CORPORATION

Rank 3

$58

9.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.